Full Year FY26 Revenue: INR 330.5 crores (vs. INR 284.9 crores in FY25; +16% YoY). Exports accounted for 65% of total formulation sales.
EBITDA Margin: Management stated formulation business EBITDA margin is "upwards of 16% to 17%" and has been consistent for the last two quarters.
Operational & Strategic Updates
Methylamines Plant (Sayakha): The backward integration facility ramped up production to nearly 1,000 tonnes per month in March 2026. Utilization was upwards of 40% in Q4 FY26 (vs. ~29% in Q3 FY26). Target is to achieve 55-60% utilization in Q1 FY27 and over 70% within a year. The project aims to reduce dependence on externally sourced inputs for the metformin portfolio.
Salicylic Acid Plant (Tarapur): Production remains shut due to variable losses. The shutdown is pending the installation of an equipment for phenol recovery, expected imminently. A multi-pronged strategy to improve profitability includes the equipment installation, developing derivatives, pursuing anti-dumping duties, and addressing effluent treatment challenges. A derivatives plant is expected to be commissioned by mid-June 2026.
Export Market Shift: The contribution of exports increased to 38% of revenue in FY26 from 35% in FY25. Within exports, the contribution from regulated markets grew to 73% from 66%.
US FDA & Approvals: The company's API plant received US FDA approval last year. Dossiers are being actively marketed for antibiotics, anti-inflammatories, and other therapies in the US, with flows expected within 12-18 months. A DMF has been filed for metformin in the US.
Oncology Formulations: The oncology plant is currently pre-revenue. Development costs are being expensed. The business is focused on signing contracts once products are at a late stage of development or near approval.
Capital Expenditure (Capex) & Financial Position
Capex Plan: A capex of INR 300-400 crores is planned over the next 2-3 years. This will be primarily brownfield or "quasi-greenfield" expansion focused on increasing capabilities in existing products and formulation capacity, including doubling the OSD capacity for non-oncology products. Part of the capex will fund oncology product development.
Capital Structure: As of March 31, 2026, consolidated long-term debt was ~INR 328 crores and short-term debt was ~INR 248 crores. The debt-to-equity ratio is stated to be at a historically low level.
Capital Work-in-Progress (CWIP): CWIP of INR 214 crores relates to a cogen boiler, brownfield expansions, and formulation R&D (primarily oncology dossier development). The amortization of the oncology-related CWIP is expected to occur mostly beyond the next 24 months.
New Project Losses: The EBITDA loss from new projects (methylamines and salicylic acid) in FY26 was estimated to be in the range of INR 18-20 crores for the full year.
Guidance & Outlook
Volume Growth: The company strives for an 8-10% volume growth annually, leveraging built-up capacity. An internal target is 10-15%.
EBITDA Margin: For FY27, the company is targeting an EBITDA margin between 13.5% and 14%. This is lower than the pre-war target of 14-14.5% due to uncertainty around crude oil prices and the West Asia conflict.
Formulation Business: The company expects to grow the formulation business to INR 1,000 crores in the next 3-5 years.
Market Dynamics: API prices are currently elevated due to the West Asia war. A prolonged period of high crude oil prices (e.g., above $110-$120/barrel) could potentially hurt domestic demand for antibiotics. Pricing trends started stabilizing from September 2025 and strengthened in Q4 FY26.
Parties Involved
Management Participants: Mr. Adhish P. Patil (COO & CFO), Mr. Harshit M. Savla (Joint Managing Director), Mr. Harit P. Shah (Whole-Time Director), Mr. Vishwa Savla (Managing Director, Pinnacle Life Science Pvt Ltd).
